Numerous studies have confirmed that MEG3 is lowly expressed in various tumors, such as CRC (102), bladder cancer (103), and renal cell cancer (104), and inhibits their migration, invasion, and metastasis. This evidence concerns the gene MEG3 and colorectal carcinoma.